MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles

作者：Rasaneh Samira; Rajabi Hossein^*; Babaei Mohammad Hossein; Akhlaghpoor Shahram

来源：Journal of Nanoparticle Research, 2011, 13(6): 2285-2293.

DOI：10.1007/s11051-010-9991-5

• Iron oxide nanoparticles
• Trastuzumab
• HER2 receptor
• MRI
• Contrast agent
• Imaging
• Nanomedicine

In this study, Trastuzumab modified Magnetic Nanoparticles (TMNs) were prepared as a new contrast agent for detecting HER2 (Human epidermal growth factor receptor-2) expression tumors by magnetic resonance imaging (MRI). TMNs were prepared based on iron oxide nanoparticles core and Trastuzumab modified dextran coating. The TMNs core and hydrodynamic size were determined by transmission electron microscopy and dynamic light scattering. TMNs stability and cytotoxicity were investigated. The ability of TMNs for HER2 detection were evaluated in breast carcinoma cell lines (SKBr3 and MCF7 cells) and tumor-bearing mice by MRI and iron uptake determination. The particles core and hydrodynamic size were 9 +/- A 2.5 and 41 +/- A 15 nm (size range: 15-87 nm), respectively. The molar antibody/nanoparticle ratio was 3.1-3.5. TMNs were non-toxic to the cells below the 30 mu g (Fe)/mL concentration and good stable up to 8 weeks in PBS buffer. TMNs could detect HER2 oncogenes in the cells surface with imagable contrast by MRI. The invivo study in mice bearing tumors indicated that TMNs possessed a good diagnostic ability as HER2 specific contrast agent by MRI. TMNs were demonstrated to be able to selectively accumulate in the tumor cells, with a proper signal enhancement in MRI T2 images. So, the complex may be considered for further investigations as an MRI contrast agent for detection of HER2 expression tumors in human.

• 出版日期2011-6